Dexamethasone nanomedicines for COVID-19

Twan Lammers, Alexandros Marios Sofias, Roy van der Meel, Raymond Schiffelers, Gert Storm, Frank Tacke, Steffen Koschmieder, Tim H Brümmendorf, Fabian Kiessling, Josbert M Metselaar

Research output: Contribution to journalArticleAcademicpeer-review


Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.
Original languageEnglish
Pages (from-to)622-624
Number of pages3
JournalNature Nanotechnology
Issue number8
Publication statusPublished - Aug 2020


  • Betacoronavirus/drug effects
  • COVID-19
  • Coronavirus Infections/drug therapy
  • Dexamethasone/therapeutic use
  • Humans
  • Nanomedicine
  • Pandemics
  • Pneumonia, Viral/drug therapy
  • SARS-CoV-2


Dive into the research topics of 'Dexamethasone nanomedicines for COVID-19'. Together they form a unique fingerprint.

Cite this